Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02978625 · ClinicalTrials.gov registry record · Phase 2
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
A Phase 2 study of Anaplastic Large Cell Lymphoma, ALK-Positive and Anaplastic Large Cell Lymphoma, ALK-negative, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
- 20
- Study locations
NCT02978625 is a Phase 2 study of Anaplastic Large Cell Lymphoma, ALK-Positive and Anaplastic Large Cell Lymphoma, ALK-negative that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 68 participants, above the 53-participant average among 4 other Anaplastic Large Cell Lymphoma, ALK-Positive trials with a reported enrollment target (28% higher). The trial reports 20 study locations across 7 states.
The verdict
NCT02978625, a Phase 2 study of Anaplastic Large Cell Lymphoma, ALK-Positive and Anaplastic Large Cell Lymphoma, ALK-negative, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase II trial studies how well talimogene laherparepvec and nivolumab work in treating patients with lymphomas that do not responded to treatment (refractory) or non-melanoma skin cancers that have spread to other places in the body (advanced) or do not responded to treatment. Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop tumor cells from growing. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving talimogene laherparepvec and nivolumab may work better compared to usual treatments in treating patients with lymphomas or non-melanoma skin cancers.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- PROCEDURE Biopsy Procedure
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Nivolumab
Study Locations (20)
Florida
- UM Sylvester Comprehensive Cancer Center at Aventura - Aventura
- UM Sylvester Comprehensive Cancer Center at Coral Gables - Coral Gables
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach - Deerfield Beach
- University of Miami Miller School of Medicine-Sylvester Cancer Center - Miami
- UM Sylvester Comprehensive Cancer Center at Kendall - Miami
- UM Sylvester Comprehensive Cancer Center at Plantation - Plantation
California
- Los Angeles General Medical Center - Los Angeles
- USC / Norris Comprehensive Cancer Center - Los Angeles
- UC Irvine Health/Chao Family Comprehensive Cancer Center - Orange
- Keck Medical Center of USC Pasadena - Pasadena
- University of California Davis Comprehensive Cancer Center - Sacramento
Kansas
- University of Kansas Clinical Research Center - Fairway
- University of Kansas Cancer Center-Overland Park - Overland Park
- University of Kansas Hospital-Indian Creek Campus - Overland Park
- University of Kansas Hospital-Westwood Cancer Center - Westwood
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
- Dana-Farber Cancer Institute - Boston
Colorado
- UCHealth University of Colorado Hospital - Aurora
Illinois
- Northwestern University - Chicago
Maryland
- Johns Hopkins University/Sidney Kimmel Cancer Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2017-09-27 |
| Est. Completion | 2027-09-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02978625
The ClinicalTrials.gov registry entry for NCT02978625 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 53-participant average among 4 other Anaplastic Large Cell Lymphoma, ALK-Positive trials with a reported enrollment target (28% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Anaplastic Large Cell Lymphoma, ALK-Positive appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT02978625 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, California, Kansas.
Frequently Asked Questions
What is clinical trial NCT02978625 about?
NCT02978625 is a clinical study titled "Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers". This phase II trial studies how well talimogene laherparepvec and nivolumab work in treating patients with lymphomas that do not responded to treatment (refractory) or non-melanoma skin cancers that have spread to other places in the body (advanced) or do not responded to treatment. Biological thera...
What is the current status of trial NCT02978625?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2017-09-27. Estimated completion is 2027-09-01.
What conditions does trial NCT02978625 study?
This clinical trial studies the following conditions: Anaplastic Large Cell Lymphoma, ALK-Positive, Anaplastic Large Cell Lymphoma, ALK-negative, Extramammary Paget Disease, Apocrine Carcinoma, Carcinoma Arising From Cylindroma.
What interventions are being tested in trial NCT02978625?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Biopsy Procedure (PROCEDURE), Laboratory Biomarker Analysis (OTHER), Nivolumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02978625?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02978625 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anaplastic Large Cell Lymphoma, ALK-Positive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL
ACTIVE NOT RECRUITING · Phase 2
-
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
RECRUITING · Phase 1
-
Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma
COMPLETED · Phase 1
Explore more on PlainTrial
Anaplastic Large Cell Lymphoma, ALK-Positive
All registered trials for this condition
Anaplastic Large Cell Lymphoma, ALK-negative
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.